Does thyroid stunning exist? A model with benign thyroid disease

摘要: With regard to the treatment of differentiated non-medullary thyroid carcinoma, there is controversy over whether radiation from a diagnostic radioiodine (131I) application really does have suppressive effect on uptake subsequent therapeutic 131I (so-called stunning). However, inherent difficulties in exact remnant/metastatic tissue volumetry make it difficult quantify how much actually absorbed (absorbed energy dose) and hence decide threshold dose exists beyond which such stunning would occur. Since benign disease target volume can be readily quantified by ultrasonography, we sought determine definitely cells occurs upon second 4 days following first one. We therefore studied 171 consecutive patients with (diffuse goitre, Graves' disease, toxic nodular goitre) who received two-step therapy during single in-patient stay. For both calculated activities performed kinetic dosimetry uptake, effective half-life dose. At application, showed significant (a 31.7% decrease 34.7%±15.4% at 23.7%±12.3% P 0.2). ANOVA that extent was influenced significantly only (F=13.5, 0.4). There no correlation between first-application activity (r=0.07, P>0.3), whereas highly (r=0.64, P<0.00005), latter fitting logarithmic model best. Multivariate factor analysis also revealed decisive factor. In conclusion, our study confirms conditions purely radiobiological inhibitory phenomenon related